Search research articles
Contact Us
Filters
Showing results (101-110 of 129) with videos related to
Page
of 13
Sort By:
Blood
|
February 4, 2010
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
Jonathan R Lambert, Jamshed B Bomanji, Karl S Peggs, et al.
British Journal of Haematology
|
November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
Katharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Blood Advances
|
December 24, 2019
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Emma Das-Gupta, Kirsty J Thomson, Adrian J C Bloor, et al.
Blood
|
May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol
Marc R Mansour, Maria L Sulis, Veronique Duke, et al.
The Lancet. Haematology
|
April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
Michael Northend, William Wilson, Kushani Ediriwickrema, et al.
The Lancet. Oncology
|
March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Kirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Nature Medicine
|
November 14, 2017
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, et al.
Journal of the National Cancer Institute
|
August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphoma
Anthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 129) with videos related to
Sort By:
Page
of 13
Blood
|
February 4, 2010
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
Jonathan R Lambert, Jamshed B Bomanji, Karl S Peggs, et al.
British Journal of Haematology
|
November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
Katharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Blood Advances
|
December 24, 2019
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Emma Das-Gupta, Kirsty J Thomson, Adrian J C Bloor, et al.
Blood
|
May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol
Marc R Mansour, Maria L Sulis, Veronique Duke, et al.
The Lancet. Haematology
|
April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
Michael Northend, William Wilson, Kushani Ediriwickrema, et al.
The Lancet. Oncology
|
March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Kirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Nature Medicine
|
November 14, 2017
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, et al.
Journal of the National Cancer Institute
|
August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphoma
Anthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Page
of 13